Tarsus PharmaceuticalsTARS -2.21%48 Days Inventory is 43.43 as of Mar. 2026, which is 47% below its 10-year median of 81.49. GuruFocus rates TARS with a GF Score™ of 48/100 and a GF Value™ of $202.09 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 640 Biotechnology companies, Tarsus Pharmaceuticals ranks better than 88.44% on this metric.
The historical rank and industry rank for Tarsus Pharmaceuticals's Days Inventory or its related term are showing as below:
TARS'
s Days Inventory Range Over the Past 10 Years
Min: 40.53 Med: 81.49 Max: 711.9
Current: 40.53
During the past 8 years, Tarsus Pharmaceuticals's highest Days Inventory was 711.90. The lowest was 40.53. And the median was 81.49.
TARS's Days Inventory is ranked better than 88.44% of 640
companies
in the Biotechnology industry
Industry Median: 184.145
vs TARS: 40.53
Tarsus Pharmaceuticals's Days Inventory
declined
from Mar. 2025 (46.62) to Mar. 2026 (43.43).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Tarsus Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 2.10.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Tarsus Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.03.
Tarsus Pharmaceuticals (NAS:TARS) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Tarsus Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Tarsus Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Tarsus Pharmaceuticals Days Inventory Related Terms
Tarsus Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Tarsus Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TARS vs VERA, IDYA, MLYS: Days Inventory Comparison
For the Biotechnology subindustry, Tarsus Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsus Pharmaceuticals Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals (TARS) has a Days Inventory of 43.43 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Tarsus Pharmaceuticals and its competitors. This is 47% below median its historical median of 81.49. Over the past decade, Tarsus Pharmaceuticals' Days Inventory has ranged from 40.53 to 711.90. According to the industry distribution chart, Tarsus Pharmaceuticals ranks #74 out of 640 companies in the Biotechnology industry, placing it in the top 11.6%.
Is Tarsus Pharmaceuticals' Days Inventory too high?
Tarsus Pharmaceuticals' current Days Inventory of 43.43 is 47% below median its 10-year median of 81.49. Over the past 10 years, this metric has ranged from a low of 40.53 to a high of 711.90. The Biotechnology industry median Days Inventory is 184.15. Tarsus Pharmaceuticals' value of 43.43 is 76.4% below this industry median. Based on the distribution chart, Tarsus Pharmaceuticals ranks #74 out of 640 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tarsus Pharmaceuticals has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Days Inventory compare to VERA and IDYA?
According to the Biotechnology industry distribution chart, Tarsus Pharmaceuticals ranks #74 out of 640 companies for Days Inventory. This places Tarsus Pharmaceuticals in the top 12% of its industry — outperforming the majority of peers. The industry median Days Inventory is 184.15. Tarsus Pharmaceuticals' value of 43.43 is 76.4% below this benchmark. Historically, Tarsus Pharmaceuticals' own Days Inventory has ranged from 40.53 to 711.90 over the past decade. While the company's 10-year median is 81.49 vs. the industry median of 184.15, Tarsus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.15, based on 640 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tarsus Pharmaceuticals's current Days Inventory of 43.43 is 76.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Tarsus Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Inventory is 184.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsus Pharmaceuticals's current Days Inventory is 43.43, which is 47% below median its own 10-year median of 81.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Possible Value Trap. The stock's GF Value™ is $202.09, compared to a current price of $62.92 — trading 68.9% below its estimated fair value. The current Days Inventory is 43.43, which is 47% below median its 10-year median of 81.49 and 76.4% below the Biotechnology industry median of 184.15. Tarsus Pharmaceuticals' overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Days Inventory is 43.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued.
The current stock price of $62.92 is trading 68.9% below its estimated GF Value™ of $202.09.
GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TARS:
Days Inventory: 43.43 (47% below median its 10-year median of 81.49)
GF Value™: $202.09 vs. price of $62.92 (68.9% below fair value)
Industry Position: 76.4% below the Biotechnology median (#74 of 640)
No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
48GF Score
Get the complete analysis for TARS
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARS has been successfully added to your 
